Kestrel Therapeutics doses first patient in FALCON pan-KRAS trial
Kestrel Therapeutics has dosed the first patient in FALCON, its Phase 1 trial of KST-6051, an oral pan-KRAS inhibitor being evaluated in patients with advanced or metastatic solid tumours harbouring KRAS mutations. The Watertown, Massachusetts-based company simultaneously announced a warrant agreement with AbbVie, under which the global biopharmaceutical firm gains an exclusive option to acquire Kestrel upon the completion of defined development and regulatory milestones.
The headline figure attached to the deal is up to $1.45 billion, encompassing an upfront payment, future exercise payments, and downstream milestone payments. AbbVie will also support funding of the KST-6051 programme during the development period. Financial terms beyond the total potential value were not disclosed.
The science behind KST-6051
KST-6051 is designed to bind KRAS in both its active (GTP-bound) and inactive (GDP-bound) conformations, distinguishing it from earlier mutation-specific inhibitors such as sotorasib and adagrasib, which target only the KRAS G12C variant. The company says the compound selectively spares HRAS and NRAS, a feature it argues may reduce the off-target toxicity risks associated with broader pan-RAS inhibition. Preclinical data, according to Kestrel, showed on-target pathway modulation and anti-proliferative activity at well-tolerated doses across multiple human KRAS-mutant tumour models.
Chief executive Frank Haluska said the AbbVie agreement represented "a major validation" of the pan-KRAS programme, while Eleni Lagkadinou, AbbVie's Vice President of Oncology Early Development, noted that pan-KRAS inhibitors could complement the company's existing pipeline of antibody-drug conjugates and immunotherapies.
The FALCON study (KST-6051-101) is an open-label, multicentre, dose-escalation trial. It will enrol patients with advanced solid tumours who have progressed on standard therapies, with expansion cohorts planned in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer — indications that together represent a substantial proportion of KRAS-driven disease burden. Primary endpoints cover safety, tolerability, and determination of the recommended dose for expansion; secondary objectives include pharmacokinetics, pharmacodynamics, and preliminary antitumour activity.
Market context and competitive landscape
The KRAS inhibitor space has expanded rapidly since the first approval of sotorasib by the FDA in 2021. However, mutation-specific G12C agents address only a subset of the estimated 20% of all malignancies that carry a KRAS alteration. The broader pan-KRAS opportunity — covering G12D, G12V, and other common variants particularly prevalent in pancreatic and colorectal cancers — has attracted significant pipeline investment from Revolution Medicines, Mirati Therapeutics (now part of BMS), and a number of earlier-stage companies. Resistance mechanisms and the tolerability of systemic RAS pathway suppression remain open questions that clinical data will need to address.
AbbVie's structured option-to-acquire approach, rather than an outright licence or acquisition, reflects a wider industry pattern of de-risking large oncology bets at the clinical-stage entry point. For Kestrel — backed by Pfizer Ventures and Santé Ventures — the arrangement provides both capital and a credible commercial pathway without requiring an immediate exit. Investors will look to early FALCON dose-escalation readouts for evidence that KST-6051's dual-state binding mechanism translates into the durable pathway suppression the company is projecting. The trial is registered at ClinicalTrials.gov under NCT07458347.